Broadfin Capital Closes on Agreements with BioDelivery Sciences on Comprehensive Plan to Strengthen Business

Firm News

Olshan client Broadfin Capital announced that it has closed on its previously announced agreements with BioDelivery Sciences International, Inc. (NASDAQ: BDSI) providing for the reconstitution of BDSI’s board of directors and a $50 million equity financing led by Broadfin.  Pursuant to the agreements, Broadfin Managing Partner Kevin Kotler and two other independent directors selected by Broadfin joined BDSI’s board of directors, and four members of the board voluntarily retired, leaving the size of the board at seven directors (also including BDSI’s newly-appointed CEO).  Olshan Shareholder-Activism Co-chair Steve Wolosky and partner Kenneth Mantel advised Broadfin Capital in connection with its investment in BDSI. 

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.